For the state, the cost of funding obesity medications was too high. For the patients, the cost of losing access is higher.

The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...

Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

Amgen (Nasdaq: AMGN) is investing more than $1 billion to expand its operations in Holly Springs, where the company already ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...